Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
NCT ID: NCT00630721
Last Updated: 2018-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
56 participants
INTERVENTIONAL
2007-09-30
2011-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
NCT00468182
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
NCT03347370
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
NCT02903537
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
NCT01198132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IFNbeta-1b
no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
IFNbeta-1b
no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IFNbeta-1b
no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-60 years, inclusive
* Expanded disability status of 0-6.5
* Give written informed consent prior to any testing under this protocol
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silva Markovic-Plese, MD
Role: PRINCIPAL_INVESTIGATOR
UNC Chapel Hill
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-0941
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.